QQ客服 官方微博 反馈留言

浏览/检索结果: 共14条，第1-10条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Primary results from TAIL, a global single-arm safety study of atezolizumab (atezo) monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer (NSCLC) 会议论文 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SEP 27-OCT 01, 2019 作者:  Ardizzoni, A.;  Azevedo, S.;  Rubio Viquiera, B.;  Rodriguez Abreu, D.;  Alatorre-Alexander, J. 收藏  |  浏览/下载：16/0  |  提交时间：2019/12/31 Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung 会议论文 作者:  Goss, G.;  Cobo, M.;  Lu, S.;  Syrigos, K.;  Lee, K. H. 收藏  |  浏览/下载：10/0  |  提交时间：2019/12/05 lung SCC  Afatinib  erlotinib  ErbB mutations   Afatinib versus erlotinib as second-line treatment of patients (pts) with advanced lung squamous cell carcinoma (SCC): Final analysis of the global phase III LUX-Lung 8 (LL8) trial 期刊论文 ANNALS OF ONCOLOGY, 2018, 卷号: 29 作者:  Cseh, A.;  Felip, E.;  Bender, S.;  Goss, G. D.;  Cobo, M. 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/05 Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung 期刊论文 JOURNAL OF THORACIC ONCOLOGY, 2017, 卷号: 12, 期号: 11 作者:  Goss, G.;  Felip, E.;  Cobo, M.;  Lu, S.;  Syrigos, K. 收藏  |  浏览/下载：9/0  |  提交时间：2019/12/05 NSCLC  Squamous cell carcinoma  afatinib   Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders 会议论文 作者:  Li, W.;  Gadgeel, S. M.;  Soria, J. C.;  Felip, E.;  Cobo, M. 收藏  |  浏览/下载：6/0  |  提交时间：2019/12/05 Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders 期刊论文 EUROPEAN JOURNAL OF CANCER, 2017, 卷号: 72 作者:  Goss, G.;  Cobo, M.;  Lu, S.;  Soria, J. C.;  Syrigos, K. 收藏  |  浏览/下载：11/0  |  提交时间：2019/12/05 Second-line afatinib vs erlotinib for patients with squamous cell carcinoma of the lung in LUX-Lung 8: analysis of tumor and serum biomarkers 期刊论文 ANNALS OF ONCOLOGY, 2016, 卷号: 27 作者:  Lee, K. H.;  Soria, J-C.;  Felip, E.;  Cobo, M.;  Lu, S. 收藏  |  浏览/下载：6/0  |  提交时间：2019/12/05 Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8). 期刊论文 JOURNAL OF CLINICAL ONCOLOGY, 2015, 卷号: 33, 期号: 15 作者:  Soria, Jean-Charles;  Felip, Enriqueta;  Cobo, Manuel;  Lu, Shun;  Syrigos, Konstantinos N. 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/05 Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial. 期刊论文 JOURNAL OF CLINICAL ONCOLOGY, 2015, 卷号: 33, 期号: 15 作者:  Gadgeel, Shirish M.;  Dols, Manuel Cobo;  Felip, Enriqueta;  Soria, Jean-Charles;  Lee, Ki Hyeong 收藏  |  浏览/下载：10/0  |  提交时间：2019/12/05 Phase III trial of afatinib vs erlotinib in patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8): EGFR molecular aberrations and survival outcomes 期刊论文 EUROPEAN JOURNAL OF CANCER, 2015, 卷号: 51 作者:  Goss, G. D.;  Felip, E.;  Cobo, M.;  Lu, S.;  Syrigos, K. 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/05